| Page 2176 | Kisaco Research
 

Catherine Salway

Founder and CEO
Redemption

Catherine Salway is the founder and CEO of Redemption, London’s healthiest restaurants with the ethos, ‘spoil yourself without spoiling yourself’ – alcohol-free, vegan, wheat-free and sugar-free. Described by The Sunday Times as a ‘cool new vegan place’, and according to Time Out, ‘worth staying sober for’.

Catherine studied economics at university then joined Virgin for 17 years where she worked her way up to Virgin Group Brand Director.

Catherine Salway

Founder and CEO
Redemption

Catherine Salway

Founder and CEO
Redemption

Catherine Salway is the founder and CEO of Redemption, London’s healthiest restaurants with the ethos, ‘spoil yourself without spoiling yourself’ – alcohol-free, vegan, wheat-free and sugar-free. Described by The Sunday Times as a ‘cool new vegan place’, and according to Time Out, ‘worth staying sober for’.

Catherine studied economics at university then joined Virgin for 17 years where she worked her way up to Virgin Group Brand Director.

Twitter @CatherineSalway

 

 

Prith Banerjee

SVP, Innovation
Synopsys

Prith Banerjee is Senior Vice President of Innovation at Synopsys.  Prith leads the Synopsys Innovation Group (SIG) which fosters advancements in EDA, Simulation & Analysis, and IP. Working closely with Fellows, Chief Technologists, Architects, and the Technical Leadership team, SIG shapes the company’s technology strategy and fosters cross-functional collaboration. The group engages with customers, partners, startups, and academia to refine and share Synopsys’ technology vision.

Prith Banerjee

SVP, Innovation
Synopsys

Prith Banerjee

SVP, Innovation
Synopsys

Prith Banerjee is Senior Vice President of Innovation at Synopsys.  Prith leads the Synopsys Innovation Group (SIG) which fosters advancements in EDA, Simulation & Analysis, and IP. Working closely with Fellows, Chief Technologists, Architects, and the Technical Leadership team, SIG shapes the company’s technology strategy and fosters cross-functional collaboration. The group engages with customers, partners, startups, and academia to refine and share Synopsys’ technology vision.

Prior to joining Synopsys, Prith served as Chief Technology Officer at Ansys, where he was responsible for guiding the company’s long-term technology vision. He has held multiple senior leadership roles across technology and industrial organizations, including Executive Vice President and Chief Technology Officer at Schneider Electric, Chief Technology Officer and Executive Vice President at ABB in Zurich,and Managing Director of Global Technology R&D at Accenture. He also served as Senior Vice President of Research and Director of HP Labs at Hewlett-Packard, where he oversaw global innovation efforts.

Earlier in his career, Prith was a leader in academia, serving as Dean of the College of Engineering at the University of Illinois at Chicago and as Chairman of the Electrical and Computer Engineering Department at Northwestern University. He began his academic career as a professor at the University of Illinois at Urbana-Champaign.

A serial entrepreneur, Prith founded AccelChip, an EDA software company acquired by Xilinx, and BINACHIP, where he served as Founder, Chairman, and Chief Scientist. His research interests span electronic design automation and parallel computing, and he is the author of over 350 technical papers and has supervised 37 Ph.D. students.

Prith has been widely recognized for his contributions to technology and innovation. He was named one of Fast Company’s Top 100 Business Leaders in 2009 and is a Fellow of AAAS, ACM, IEEE and National Academy of Inventors. He is also a recipient of the ASEE Terman Award and the NSF Presidential Young Investigator Award.

He earned his B.Tech. in Electronics Engineering from the Indian Institute of Technology, Kharagpur, where he was awarded the President’s Gold Medal. He holds an M.S. and Ph.D. in Electrical Engineering from the University of Illinois at Urbana-Champaign.

 

Leslie C. North

President & CEO
Medicem, Inc.

Leslie C. North

President & CEO
Medicem, Inc.

Leslie C. North

President & CEO
Medicem, Inc.
 
26-27 Nov 2019
Frankfurt
 The Targeting RNA congress will discuss the latest advancements in modulation of RNA (splicing/non-coding/micro) directly with small molecules and through epigenetics. The meeting will showcase structures of small molecules binding to disease relevant RNA and innovations in building hit-to-lead RNA specific platforms both essential for proof-of concept.Bringing together leaders in academics and industry such as Novartis, Merck, Gotham Therapeutics and University of Cambridge, who are building platforms to identify and validate targets, in order to assess in disease relevance approaches in the relatively untapped RNA world. The meeting will also discuss translational strategies, addressing structural biology, biochemical and biophysical attributes, chemical hurdles associated with new drug discovery platforms.What to expect:Opportunities to engage with key players from biotech, pharma, and academia that are building platforms to target RNA with small molecules, modify the RNA with enzymes (epigenetics) and indirectly through protein-RNA interactions.Hear how to overcome 2D structural biology parameters from leading European RNA biologists and computational biologists and emerging European epigenetics companies.The first European translational event focusing on modifying RNA upstream regulation to enable preventive medicine instead of treating symptoms with small molecules and epitranscriptomics.A meeting bridging the gap between the key research challenges such as target identification (chemo-proteomics, 2D/3D structures) and validation (small molecule binding efficiencies, selectivity and stability) and sharing new methodologies and process for obtaining hit to lead products in the RNA space.
 

Adam Lisberg

Corporate Communications Director
DJI

Adam Lisberg

Corporate Communications Director
DJI

Adam Lisberg

Corporate Communications Director
DJI
 

Douglas Moule

Operations Manager
easyJet

Douglas Moule

Operations Manager
easyJet

Douglas Moule

Operations Manager
easyJet
 

Brendan Booth

Safety Manager
easyJet

Brendan Booth

Safety Manager
easyJet

Brendan Booth

Safety Manager
easyJet
Millie Kendall on the Beauty Industry
 
WOMEN IN TARGETING THE UNDRUGGED
16-24 Feb 2021
VIRTUAL CONGRESS | EST TIMEZONE
The targeted protein degradation field is expanding, gone are the days of simple proof of concept…. We now have LYTACs, AUTACs and ATTECs as well as numerous PROTAC and Molecular Glue companies with millions of dollars worth of investment. C4 netted $182.4 million in IPO, and Nurix and Kymera closed funding with $120 million and $102 million apiece. With several start-ups launching, including Lycia and Amphista therapeutics, investment in this area is booming, and it’s not slowing down.There are currently over 85 degraders being considered at various stages of development, both preclinical and clinical, as well as in discovery. However, key questions are yet to be answered:How will degrader research translate in the clinic?Why are we still struggling with oral bioavailability?How can we effectively validate novel targets and degrade ‘undruggable’ targets of interest?What can be learned from the new, emerging degrader strategies that are emerging?Once again bringing together leaders from pharma, biotech and academia as well as innovative service providers, the North American Protein Degradation Congress is back to give you the full picture from molecular biology right the way up to the latest in medicinal chemistry and clinical data.Learn to create clinically applicable degraders to the entire proteome at the digital North American Protein Degradation Congress 2021.